GLENMARK Glenmark Pharmaceuticals Q3 FY25 results (Oct–Dec 2024) and concall
Glenmark Pharmaceuticals reported a strong Q3 FY25 with consolidated revenue growing 35.1% YoY, significantly boosted by a 300% growth in India formulations. Europe also showed robust growth, while North America remained challenging. The company is optimistic about future launches in the US respiratory segment and expects RYALTRIS sales to reach $80 million in FY25. Net debt was significantly reduced to INR 109 crores.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 2,636 | 2,251 |
| EBITDA | 779 | 494 |
| Net profit | 595 | 414 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
